Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

• DOI: 10.1073/pnas.0703395104
• Publication Date: 2007-05-16T01:41:18Z
• Authors: Danila Valmori; Naira E. Souleima...; Valeria Tosello; Nina Bhardwaj; Sylvia Adams; David O'Neill; Anna Pavlick; Juliet B. Escalon; Crystal M. Cruz; Angelica Angiulli; Francesca Angiulli; Gregory Mears; Susan M. Vogel; Linda Pan; Achim A. Jungbluth; Eric W. Hoffmann; Ralph Venhaus; Gerd Ritter; Lloyd J. Old; Maha Ayyoub
• Keywords: Priming (agriculture); Cancer vaccine; Cancer Immunotherapy

The use of recombinant tumor antigen proteins is a realistic approach for the development generic cancer vaccines, but potential this type vaccines to induce specific CD8(+) T cell responses, through in vivo cross-priming, has remained unclear. In article, we report that repeated vaccination patients with NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, potent stimulator B cells helper 1 (Th1)-type immunity, resulted early induction integrated CD4(+) Th antibody responses most vaccinated patients, followed by later fraction them. correlation between together ability vaccine-induced antibodies promote vitro cross-presentation dendritic cells, indicated elicitation NY-ESO-1-specific cross-priming was associated adequate levels antibodies. Together, our data provide clear evidence cytotoxic lymphocytes vaccine, underline importance occur, support formulation further efficient vaccines.